OrthoPediatrics (NASDAQ:KIDS - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. OrthoPediatrics had a negative return on equity of 5.44% and a negative net margin of 14.35%. The business had revenue of $52.80 million during the quarter, compared to analyst estimates of $52.40 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
OrthoPediatrics Stock Up 1.5 %
KIDS stock traded up $0.41 during trading on Wednesday, reaching $27.00. The stock had a trading volume of 101,622 shares, compared to its average volume of 165,158. The company has a quick ratio of 1.96, a current ratio of 4.90 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $643.38 million, a price-to-earnings ratio of -27.70 and a beta of 1.17. The company's 50 day moving average is $28.34 and its two-hundred day moving average is $29.92. OrthoPediatrics has a one year low of $23.84 and a one year high of $36.23.
Insiders Place Their Bets
In related news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $29.30, for a total transaction of $293,000.00. Following the transaction, the general counsel now owns 77,304 shares in the company, valued at $2,265,007.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 31.80% of the company's stock.
Analyst Ratings Changes
Several research analysts recently weighed in on KIDS shares. Truist Financial decreased their price objective on shares of OrthoPediatrics from $34.00 to $28.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Friday, September 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $50.00 price objective on shares of OrthoPediatrics in a research note on Friday, September 13th.
Read Our Latest Report on KIDS
About OrthoPediatrics
(
Get Free Report)
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Stories
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
